With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.125995-03-1,Atorvastatin lactone,as a common compound, the synthetic route is as follows.
Example 3. Synthesis of Atorva-HA ((3R,5R)-7-[2-(4-Fluoro-phenyl)-5-isopropyl-3- phenyl-4-phenylcarbamoyl pyrrol-l-yl]-3,5-dihydroxy-N-hydroxyheptanamide) [00356] By a procedure similar to Lova-HA, atorvastatin (168 mg, 0.31 mmol, in the lactone form) was treated with MgBr2 (115 mg, 0.62 mmol), hydroxylamine hydrochloride (184 mg, 2.6 mmol), and sodium bicarbonate (209 mg, 2.5 mmol) in anhydrous THF/MeOH (7:3, 1 mL) at ambient temperature for 20 h to give Atorva-HA (91 mg, 51%). The purity was 95% as shown by HPLC analysis on an HC-Cig column (Agilent, 4.6 x 250 mm, 5 muiotaeta), tR = 14.8 min (gradients of 30-100%) aqueous CH3CN in 30 min). C33H36FN305; colorless oil; [alpha]26omicron = -1.3 (EtOAc, c = 1.0); TLC (CH2Cl2/MeOH (9: 1)) Rf= 0.33; IR vmax (neat) 3405, 3301, 3059, 2960, 2926, 1738, 1657, 1595, 1527, 1508, 1436, 1314, 1241, 1223, 1157, 1108, 1078, 1046, 843, 753, 692 cm”1; 1H NMR (DMSO-< 6, 400 MHz) delta 10.31 (1 H, br s), 9.77 (1 H, br s), 8.68 (1 H, br s), 7.50 (2 H, d, J= 7.6 Hz), 7.18-7.24 (6 H, m), 7.07 (4 H, br s), 6.98-7.00 (2 H, m), 4.69 (1 H, br s), 4.60 (1 H, d, J= 4.0 Hz), 3.92-3.95 (1 H, m), 3.72-3.83 (2 H, m), 3.53 (1 H, br s), 3.21-3.25 (1 H, m), 2.01 (2 H, d, J= 6.0 Hz), 1.63 (1 H, br s), 1.53 (1 H, br s), 1.28-1.38 (8 H, m) ppm; 13C NMR (DMS0 , 100 MHz) delta 167.4, 166.1, 162.8, 160.3, 139.4, 135.9, 134.9, 133.4, 129.1 (2 x), 128.7, 128.4 (2 chi), 127.6 (2 chi), 127.3, 125.3, 122.9, 120.6, 119.4 (2 chi), 117.5, 115.4, 115.2, 66.0, 65.6, 43.8, 40.9, 40.7, 25.6, 22.3 (2 chi) ppm; ESI-HRMS (negative mode) calcd. for C33H35FN305: 572.2561, found: m/z 572.2562 [M - H] . 125995-03-1, The synthetic route of 125995-03-1 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; ACADEMIA SINICA; NATIONAL TAIWAN UNIVERSITY; LIANG, Chi-Ming; CHEN, Ching-Chow; CHEN, Jhih-Bin; WEI, Tzu-Tang; LIN, Jung-Hsin; FANG, Jim-Min; CHERN, Ting-Rong; WO2014/15235; (2014); A2;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics